Saturday 17 October 2026
Export XRAY’s income statement to Excel — free account
DENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue fell 4.06%, EPS grew 181.8%, free cash flow grew 252.9% and total debt fell 10.0%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years; insiders bought in the last twelve months.
8.57
0.26
−2.94%
Follow XRAY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.70 | 0.62 | 0.63 | 0.58 | |
P/FCF ratio |
33.76 | 23.02 | 23.42 | 14.92 | |
P/Operating CF |
32.05 | 22.57 | 57.97 | 21.40 | |
P/B ratio |
1.71 | 1.70 | 1.76 | 1.57 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.16 | 1.08 | 1.12 | 1.06 | |
EV/EBITDA |
17.96 | 8.72 | 11.58 | 9.50 | |
EV/Operating CF |
18.94 | 16.89 | 15.43 | 12.15 | |
EV/FCF |
55.81 | 40.08 | 41.77 | 27.29 | |
Quick Ratio |
0.72 | 0.76 | 0.67 | 0.72 | |
Current Ratio |
1.47 | 1.51 | 1.53 | 1.63 | |
Net Debt/EBITDA |
13.02 | 24.13 | 41.27 | 10.52 | |
Debt/Assets |
35.68% | 37.12% | 38.36% | 38.36% | |
Debt/Equity |
1.36 | 1.50 | 1.52 | 1.48 | |
Asset Turnover |
0.59 | 0.66 | 0.65 | 0.65 | |
Operating CF/Net income |
(0.18) | (0.69) | (4.00) | 2.68 | |
Capex/Depreciation |
(0.12) | (0.20) | (0.66) | (0.46) | |
Interest Coverage |
(9.48) | (6.32) | (1.46) | 3.73 | |
Research and Development Expense of Revenue |
4.09% | 4.16% | 5.00% | 5.01% | |
Selling, General and Administrative Expense of Revenue |
39.27% | 39.85% | 39.89% | 40.53% | |
Intangible Assets out of Total Assets |
0.41 | 0.39 | 0.40 | 0.39 | |
Share Based Compensation of Revenue |
0.66% | 0.83% | 0.91% | 1.00% | |
Graham Net Nets |
(0.83) | (0.91) | (0.89) | (0.91) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(34.83%) | (26.25%) | (27.16%) | (25.92%) | |
Free Cash Flow Yield |
2.96% | 4.34% | 4.27% | 6.70% | |
Revenue per Share |
4.53 | 4.82 | 4.40 | 4.50 | |
Operating CF per Share |
0.40 | 0.51 | 0.20 | 0.50 | |
Capex per Share |
(0.20) | (0.21) | (0.26) | (0.20) | |
Free Cash Flow per Share |
0.20 | 0.30 | (0.06) | 0.30 | |
Cash per Share |
1.82 | 1.63 | 0.95 | 1.20 | |
Shareholders Equity per Share |
7.41 | 6.72 | 6.60 | 6.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.41 | 6.72 | 6.60 | 6.77 | |
Free Cash Flow |
39.00 | 60.00 | (12.00) | 60.00 | |
Working Capital |
667.00 | 680.00 | 638.00 | 743.00 | |
Capital Expenditures |
(40.00) | (41.00) | (52.00) | (39.00) | |
Net Current Asset Value |
(2,103.00) | (2,066.00) | (2,065.00) | (1,925.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.04 | 0.06 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
662.50 | 622.00 | 613.00 | 633.00 | |
Average Payables |
282.50 | 270.50 | 267.50 | 264.00 | |
Average Inventory |
652.50 | 603.00 | 635.50 | 670.00 | |
Average Assets |
6,139.50 | 5,591.00 | 5,639.50 | 5,636.50 | |
Average Common Equity |
1,984.00 | 1,641.50 | 1,664.50 | 1,656.00 |
Columns are period end dates